Radiopharm Theranostics (NASDAQ:RADX) Shares Down 8.4% – What’s Next?

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) were down 8.4% during trading on Thursday . The company traded as low as $2.23 and last traded at $2.29. 88,911 shares traded hands during trading, a decline of 41% from the average session volume of 151,981 shares. The stock had previously closed at $2.50.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HC Wainwright initiated coverage on Radiopharm Theranostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $11.00.

Radiopharm Theranostics Stock Up 6.6%

The business’s 50 day simple moving average is $3.71 and its two-hundred day simple moving average is $4.32.

Institutional Investors Weigh In On Radiopharm Theranostics

Several institutional investors have recently bought and sold shares of RADX. Hsbc Holdings PLC bought a new position in Radiopharm Theranostics in the 4th quarter valued at $1,007,000. Marex Group plc bought a new position in Radiopharm Theranostics in the 4th quarter worth approximately $54,000. Jane Street Group LLC bought a new stake in Radiopharm Theranostics during the 4th quarter valued at $76,000. Finally, Virtu Financial LLC purchased a new stake in shares of Radiopharm Theranostics during the fourth quarter worth $76,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.